Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec 15:8:12.
doi: 10.1186/1477-5751-8-12.

PALB2 variants in hereditary and unselected Finnish prostate cancer cases

Sanna Pakkanen  1 , Tiina Wahlfors, Sanna Siltanen, Mimmi Patrikainen, Mika P Matikainen, Teuvo L J Tammela, Johanna Schleutker
Affiliations

PALB2 variants in hereditary and unselected Finnish prostate cancer cases

Sanna Pakkanen et al. J Negat Results Biomed. .

Abstract

Background: PALB2 1592delT mutation is associated with increased breast cancer and suggestive prostate cancer (PRCA) risk in Finland. In this study we wanted to assess if any other PALB2 variants associate to increased PRCA risk and clinically describe patients with formerly found PALB2 1592delT mutation.

Methods: Finnish families with two or more PRCA cases (n = 178) and unselected cases (n = 285) with complete clinical data were initially screened for variants in the coding region and splice sites of PALB2. Potentially interesting variants were verified in additional set of unselected cases (n = 463).

Results: From our clinically defined sample set we identified total of six variants in PALB2. No novel variants among Finnish PRCA cases were found. Clinical characteristics of the variant carriers, including the previously described family carrying PALB2 1592delT, revealed a trend towards aggressive disease, which also applied to a few non-familial cases. Hypersensitivity to mitomycin C (MMC) of lymphoblasts from individuals from the family with 1592delT revealed haploinsufficiency among carriers with altered genotype.

Conclusions: Though any of the detected PALB2 variants do not associate to PRCA in population level in Finland it cannot be ruled out that some of these variants contribute to cancer susceptibility at individual level.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Family 310 segregating the PALB mutation. Minus-symbol signifies a person that has been screened for the PALB2 1592delT mutation, but found negative. Clinical information on this family is found in Table 2. Index person is marked with a black triangle, black square denotes persons with prostate cancer, grey circle indicates breast cancer cases and black square with white and grey corners signifies patient with prostate, stomach and skin cancers.
Figure 2
Figure 2
Mitomycin C growth inhibition in lymphoblastoid cell lines from the 310 family. Black circle and square depicts cell lines derived from affected individuals with PALB2 1592delT mutation. Black triangle signs for control sample from healthy individual.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
    Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, Dunning AM, Redman J, Scarth J, Plaskocinska I, Luccarini C, Shah M, Pooley K, Dorling L, Lee A, Adank MA, Adlard J, Aittomäki K, Andrulis IL, Ang P, Barwell J, Bernstein JL, Bobolis K, Borg Å, Blomqvist C, Claes KBM, Concannon P, Cuggia A, Culver JO, Damiola F, de Pauw A, Diez O, Dolinsky JS, Domchek SM, Engel C, Evans DG, Fostira F, Garber J, Golmard L, Goode EL, Gruber SB, Hahnen E, Hake C, Heikkinen T, Hurley JE, Janavicius R, Kleibl Z, Kleiblova P, Konstantopoulou I, Kvist A, Laduca H, Lee ASG, Lesueur F, Maher ER, Mannermaa A, Manoukian S, McFarland R, McKinnon W, Meindl A, Metcalfe K, Mohd Taib NA, Moilanen J, Nathanson KL, Neuhausen S, Ng PS, Nguyen-Dumont T, Nielsen SM, Obermair F, Offit K, Olopade OI, Ottini L, Penkert J, Pylkäs K, Radice P, Ramus SJ, Rudaitis V, Side L, Silva-Smith R, Silvestri V, Skytte AB, Slavin T, Soukupova J, Tondini C, Trainer AH, Unzeitig G, Usha L, van Overeem Hansen T, Whitworth J, Wood M, Yip CH, Yoon SY, Yussuf A, Zogopoulos G, Goldgar D, Hopper JL, Chenevix-Trench G, Pharoah P, George SHL, Balmaña J, Houdayer C, James P, El-Haffaf Z, Ehrencrona H, Janatova M, Peterlongo P, Nevanli… See abstract for full author list ➔ Yang X, et al. J Clin Oncol. 2020 Mar 1;38(7):674-685. doi: 10.1200/JCO.19.01907. Epub 2019 Dec 16. J Clin Oncol. 2020. PMID: 31841383 Free PMC article.
  • Novel germline PALB2 truncating mutations in African American breast cancer patients.
    Zheng Y, Zhang J, Niu Q, Huo D, Olopade OI. Zheng Y, et al. Cancer. 2012 Mar 1;118(5):1362-70. doi: 10.1002/cncr.26388. Epub 2011 Aug 26. Cancer. 2012. PMID: 21932393 Free PMC article.
  • Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients.
    Pelttari LM, Nurminen R, Gylfe A, Aaltonen LA, Schleutker J, Nevanlinna H. Pelttari LM, et al. BMC Cancer. 2012 Nov 23;12:552. doi: 10.1186/1471-2407-12-552. BMC Cancer. 2012. PMID: 23176254 Free PMC article.
  • Assessing interactions of two loci (rs4242382 and rs10486567) in familial prostate cancer: statistical evaluation of epistasis.
    Chen LS, Fann JC, Chiu SY, Yen AM, Wahlfors T, Tammela TL, Chen HH, Auvinen A, Schleutker J. Chen LS, et al. PLoS One. 2014 Feb 25;9(2):e89508. doi: 10.1371/journal.pone.0089508. eCollection 2014. PLoS One. 2014. PMID: 24586834 Free PMC article.
  • PALB2/FANCN: recombining cancer and Fanconi anemia.
    Tischkowitz M, Xia B. Tischkowitz M, et al. Cancer Res. 2010 Oct 1;70(19):7353-9. doi: 10.1158/0008-5472.CAN-10-1012. Epub 2010 Sep 21. Cancer Res. 2010. PMID: 20858716 Free PMC article. Review.
See all "Cited by" articles

References

    1. Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate. 1990;16:39–48. doi: 10.1002/pros.2990160105. - DOI - PubMed
    1. Finnish Cancer Registry. Cancer incidence and mortality in Finland. Cancer Statistics. 2007. http://www.cancerregistry.fi
    1. Kvale R, Auvinen A, Adami HO, Klint A, Hernes E, Moller B, Pukkala E, Storm HH, Tryggvadottir L, Tretli S, Wahlqvist R, Weiderpass E, Bray F. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007;99:1881–1887. doi: 10.1093/jnci/djm249. - DOI - PubMed
    1. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet. 2004;13(Spec No 1):R103–21. doi: 10.1093/hmg/ddh072. - DOI - PubMed
    1. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet. 2001;27:172–180. doi: 10.1038/84808. - DOI - PubMed

Publication types

MeSH terms